Innate Pharma SA
IPHA- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001598599
No open-market purchases or sales by Innate Pharma SA insiders were filed in the last 90 days; 10 institutions reported holding it in 13F filings for Q2 2026, worth $354.0K in total; no superinvestor holds it.
Other share classesIPHYF
Q4 2021 vs. Q3 2021
How the institutions holding Innate Pharma SA changed between Q3 2021 and Q4 2021.
All holders in Q4 2021All holders in Q3 2021
| Measure | Q3 2021 | Q4 2021 | Change |
|---|---|---|---|
| Holders | 18 | 16 | −2 |
| Shares | 943.1K | 1.39M | +447.1K (+47.4%) |
| Value | $5.82M | $6.52M | +$702.0K (+12.1%) |
New holders (5)
Institutions that held Innate Pharma SA at the end of Q4 2021 but not at the end of Q3 2021.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| BlackRock Inc. | 396,073 | $1.81M | 0.00% |
| Silverarc Capital Management, LLC | 184,046 | $839.0K | 0.38% |
| Alps Advisors Inc | 93,718 | $429.0K | 0.00% |
| Two Sigma Advisers, LP | 12,300 | $56.0K | 0.00% |
| Citigroup Inc | 44 | $0 | 0.00% |
Sold out (7)
Institutions that held Innate Pharma SA at the end of Q3 2021 and filed for Q4 2021 without it.
| Institution | Shares, Q3 2021 | Value, Q3 2021 |
|---|---|---|
| Balyasny Asset Management LLC | 187,484 | $1.16M |
| Affinity Asset Advisors, LLC | 125,000 | $771.0K |
| Cubist Systematic Strategies, LLC | 20,132 | $124.0K |
| LPL Financial LLC | 18,400 | $114.0K |
| Two Sigma Securities, LLC | 17,119 | $106.0K |
| Point72 Hong Kong Ltd | 943 | $6.00K |
| Vectors Research Management, LLC | 1,000 | $6.00K |